Abstract
Systemic treatment for bladder cancer is indicated in four clinical situations, including neoadjuvant therapy prior to radical cystectomy for muscle-invasive bladder cancer, adjuvant chemotherapy after cystectomy for muscle-invasive bladder cancer, as a part of bladder sparing protocols in concomitance with radiotherapy, and for treatment of advanced or metastatic disease. Chemotherapy regimens containing cisplatin are the basis of current systemic therapies for bladder cancer.